Report
Debbie Wang
EUR 100.00 For Business Accounts Only

Zimmer Biomet Makes Progress on Its Turnaround

Zimmer Biomet reported fourth-quarter performance that, again, demonstrated consistent, incremental progress toward addressing the supply, regulatory, and cultural issues that have hampered the firm over the last two years. Our fair value estimate is unchanged, as full-year performance generally met our expectations. We continue to anticipate a gradual return to growth and improved profitability in the longer term, though we still think large joint growth will lag the market in 2019. Nonetheless...
Underlying
ZIMMER BIOMET HOLDINGS INC.

Zimmer Biomet Holdings is engaged in musculoskeletal healthcare. The company's products are: Knees, which includes knee replacement surgeries; Hips, which includes hip replacement surgeries; S.E.T., which includes surgical, sports medicine, biologics, foot and ankle, extremities and trauma products; Spine and Craniomaxillofacial and Thoracic, which designs, manufactures and distributes medical devices and surgical instruments, as well as provides face and skull reconstruction products; Dental, which manufactures and/or distributes dental reconstructive implants, dental prosthetic products and dental regenerative products; and Other, which includes bone cement and office based technology products.

Provider
Morningstar
Morningstar

Morningstar, Inc. is a leading provider of independent investment research in North America, Europe, Australia, and Asia. The company offer an extensive line of products and services for individual investors, financial advisors, asset managers, and retirement plan providers and sponsors.

Morningstar provides data on approximately 530,000 investment offerings, including stocks, mutual funds, and similar vehicles, along with real-time global market data on more than 18 million equities, indexes, futures, options, commodities, and precious metals, in addition to foreign exchange and Treasury markets. Morningstar also offers investment management services through its investment advisory subsidiaries and had approximately $185 billion in assets under advisement and management as of June 30, 2016.

We have operations in 27 countries.

Analysts
Debbie Wang

Other Reports on these Companies
Other Reports from Morningstar

ResearchPool Subscriptions

Get the most out of your insights

Get in touch